Progress in research & development of interferon-antibody conjugates
10.3969/j.issn.1005-1678.2016.06.05
- VernacularTitle:干扰素－抗体偶联物的研究与开发进展
- Author:
Chenchen LI
;
Xueyan REN
;
Min WANG
;
Juan ZHANG
- Publication Type:Journal Article
- Keywords:
interferon;
IFN-antibody conjugates;
antibody;
anti-tumor
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(6):19-24
- CountryChina
- Language:Chinese
-
Abstract:
Interferon ( IFN) kills tumor through:direct tumor killing, stimulating immune response to tumor cells by activating the immune system and inhibiting tumor angiogenesis.However, its clinical application has been restrained by the deficiencies such as short half-life and severe side effects.IFN-antibody fusion can bring IFN to the vicinity of tumors using tumor specific antibody, while reducing the concentration of IFN in the rest parts of the body.Thus, system toxicity caused by IFN can be significantly lessened.We herein summarized the research and development of preclinical antibody-interferon conjugates and provide new thought on the development of IFN or antibody based fusion proteins.
